Senior Care in Park City MT
Every minute in the United States, one more person is diagnosed with Alzheimer’s. The disease is irreversible and one that slowly destroys memory and cognitive skills. But with each passing year, researchers are discovering medications and alternative therapies that are producing results and reducing cognitive decline.
Intravenous Immunoglobulin (IVIG)
IVIG has been found to reduce brain atrophy and cognitive decline in those that are in the early stages of Alzheimer’s. News Medical Life Sciences reports, “In a Sutter Institute of Medical Research study published… in the Journal of Neurology, Neurosurgery, and Psychiatry, the blood product intravenous immunoglobulin, or IVIG, was found to reduce brain atrophy and cognitive decline in patients in the early, pre-dementia phase of Alzheimer’s disease.” How does it work? IVIG was found to contain antibodies to amyloid, an abnormal brain protein found in patients with Alzheimer’s. This is the first significant breakthrough in ten years, leaving doctors hopeful that one of the keys to diminishing the effects of this disease is close at hand.
You may have heard about this painkiller currently in use to treat the pain of menstrual cramps. Researchers believe that this may be yet another key in the treatment of Alzheimer’s. In a study conducted at the University of Manchester in the United Kingdom, 20 mice were genetically modified to develop Alzheimer’s. Once they began exhibiting memory problems, half of them received mefenamic acid. These mice showed a complete reversal in memory loss. Mefenamic acid works by reducing brain inflammation that is known to damage brain cells. The next step in the development of this drug for Alzheimer’s will be human trials.
Researchers from Buck Institute Research on Aging found that by tailoring a treatment for Alzheimer’s patients that included diet, exercise, brain stimulation, sleep pattern analysis, medications, and vitamins produced remarkable improvements after 10 months.
Long-term treatment with broad spectrum antibiotics diminished amyloid plaques in mice. While the relation to humans and how to incorporate it is unclear, it is certain that further research will be conducted to determine the effects on early-stage Alzheimer’s patients.
Studies such as these offer hope for those battling this disease and their loved ones. Take each day at a time and, as a family caregiver, get the support you need. Senior care providers have cared for many seniors facing the uncertainty of this disease. They understand the challenges and know communication techniques that can ease your loved ones angst. Often, senior care providers become close companions to those in their care—a side benefit that greatly enhances the quality of life for your aging parent.
If you or an aging loved one are considering senior care in Park City, MT, please contact the caring staff at SYNERGY HomeCare today at 406-839-2390.